[1] 徐小元,丁惠国,李文刚,等.肝硬化肝性脑病诊疗指南.临床肝胆病杂志,2018,34:2076-2089.
[2] Wang JY, Zhang NP, Chi BR, et al. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol, 2013, 19: 4984-4991.
[3] Rathi S, Chopra M, Chouduri G, et al. Prevalence of minimal hepatic encephalopathy in patients with liver cirrhosis: a cross-sectional, clinicoepidemiological, multicenter, nationwide study in india: the PREDICT Study. J Clin Exp Hepatol, 2019, 9:476-483.
[4] Zhai Hui-Qin, Fan Hong, Geng Jia-Wei,et al. Gut flora and gut-derived endotoxin in minimal hepatic encephalopathy. Zhonghua Gan Zang Bing Za Zhi, 2014, 22: 104-107.
[5] Yoshimura E, Ichikawa T, Miyaaki H, et al. Screening for minimal hepatic encephalopathy in patients with cirrhosis by cirrhosis-related symptoms and a history of overt hepatic encephalopathy. Biomed Rep, 2016, 5: 193-198.
[6] Philonenko S, Rivière P, Mallet M, et al. Neurocognitive impairment is associated with erectile dysfunction in cirrhotic patients. Dig Liver Dis, 2019, 51: 850-855.
[7] De Rui M, Montagnese S, Amodio P. Recent developments in the diagnosis and treatment of covert/minimal hepatic encephalopathy. Expert Rev Gastroenterol Hepatol, 2016, 10: 443-450.
[8] Maharshi S, Sharma BC, Sachdeva S, et al. Efficacy of nutritional therapy for patients with cirrhosis and minimal hepatic encephalopathy in a randomized trial. Clin Gastroenterol Hepatol, 2016, 14: 454. e33.
[9] Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology, 2014, 60: 715-735.
[10] Moratalla A, Ampuero J, Bellot P, et al. Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver Int, 2017, 37: 212-223.
[11] Wang JY, Bajaj JS, Wang JB, et al. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: a multicenter, randomized controlled trial. J Dig Dis, 2019, 20: 547-556.
[12] Dhiman RK, Thumburu KK, Verma N, et al. Comparative efficacy of treatment options for minimal hepatic encephalopathy: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol, 2020, 18: 800-812. e25.
[13] Zucker DM, Redulla R. Lactulose management of minimal hepatic encephalopathy: a systematic review. Gastroenterol Nurs, 2019, 42: 84-94.
[14] Higuera-de-la-Tijera F, Servín-Caamaño AI, Salas-Gordillo F, et al. Primary prophylaxis to prevent the development of hepatic encephalopathy in cirrhotic patients with acute variceal bleeding. Can J Gastroenterol Hepatol, 2018:3015891.
[15] Zhang Y, Feng Y, Cao B, et al. Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis. Int J Clin Exp Med, 2015, 8: 2954-2957.
[16] Goyal O, Sidhu SS, Kishore H. Minimal hepatic encephalopathy in cirrhosis- how long to treat? Ann Hepatol, 2017, 16: 115-122.
[17] Sidhu SS, Goyal O, Parker RA, et al. Rifaximin vs lactulose in treatment of minimal hepatic encephalopathy. Liver Int, 2016, 36: 378-385.
[18] Schulz C, Schütte K, Vilchez-Vargas R, et al. Long-term effect of Rifaximin with and without Lactulose on the active bacterial assemblages in the proximal small bowel and faeces in patients with minimal hepatic encephalopathy. Dig Dis, 2019, 37:161-169.
[19] Bai M, He C, Yin Z, et al. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS. Aliment Pharmacol Ther, 2014, 40: 63-71.
[20] 钱见楚,吴一鸣.门冬氨酸鸟氨酸联合双歧三联活菌胶囊对亚临床肝性脑病患者内毒素血症及肠道微生态的影响.中国微生态学杂志, 2017, 29: 700-703.
[21] Xia X, Chen J, Xia J, et al. Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. J Int Med Res, 2018, 46: 3596-3604.
[22] Cao Q, Yu CB, Yang SG, et al. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: a meta-analysis. Hepatobiliary Pancreat Dis Int, 2018, 17: 9-16.
[23] Pratap Mouli V, Benjamin J, Bhushan Singh M, et al. Effect of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: a non-inferiority randomized controlled trial. Hepatol Res, 2015, 45: 880-889.
[24] 罗莉芬,姚春,杨小徽,等.通腑开窍法治疗轻微型肝性脑病探讨.山东中医药大学学报, 2018, 42: 387-389.
[25] 王林昌.大黄煎剂保留灌肠对轻微型肝性脑病患者内毒素、血氨水平的影响.中医临床研究, 2017, 9: 21-23.
[26] 章亮.清肠合剂保留灌肠治疗肝硬化轻微型肝性脑病的临床研究.中国中医药科技, 2015, 22: 12-14.
[27] 李晶滢,李丽.地黄饮子治疗轻微型肝性脑病的临床疗效分析.中西医结合肝病杂志, 2019, 29: 19-20.
[28] 苏红慧,崔厚松,王晓强,等.针刺十三鬼穴治疗轻微型肝性脑病的临床研究.山东中医杂志, 2017, 36: 672-674.
[29] Mousa N, Abdel-Razik A, Zaher A, et al. The role of antioxidants and zinc in minimal hepatic encephalopathy: a randomized trial. Therap Adv Gastroenterol, 2016, 9: 684-691.
[30] Cai XJ, Wang L, Hu CM. Efficacy of different drugs in the treatment of minimal hepatic encephalopathy: A network meta-analysis involving 826 patients based on 10 randomized controlled trials. J Cell Biochem, 2018, 119: 8336-8345.
[31] Arias N, Méndez M, Arias JL. Low-light-level therapy as a treatment for minimal hepatic encephalopathy: behavioural and brain assessment. Lasers Med Sci, 2016, 31: 1717-1726.
[32] Malaguarnera G, Pennisi M, Bertino G, et al. Resveratrol in patients with minimal hepatic encephalopathy. Nutrients, 2018, 10:329. |
